- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical cancer immunotherapy: Current progress and prospects
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 13, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-10-11
DOI
10.3389/fimmu.2022.961805
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer
- (2022) Alberto A. Chiappori et al. CLINICAL CANCER RESEARCH
- Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects
- (2022) Paul Shafer et al. Frontiers in Immunology
- Delivery of CAR-T cells in a transient injectable stimulatory hydrogel niche improves treatment of solid tumors
- (2022) Abigail K. Grosskopf et al. Science Advances
- Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors
- (2022) Emerson A. Lim et al. CLINICAL CANCER RESEARCH
- A phase 1b trial of the CXCR4 inhibitor mavorixafor and nivolumab in advanced renal cell carcinoma patients with no prior response to nivolumab monotherapy
- (2021) Toni K. Choueiri et al. INVESTIGATIONAL NEW DRUGS
- Checkpoint inhibition through small molecule-induced internalization of programmed death-ligand 1
- (2021) Jang-June Park et al. Nature Communications
- A burned-out CD8+ T-cell subset expands in the tumor microenvironment and curbs cancer immunotherapy
- (2021) Miguel F Sanmamed et al. Cancer Discovery
- Discovery of a novel, potent and selective small‐molecule inhibitor of PD‐1/PD‐L1 interaction with robust in vivo anti‐tumour efficacy
- (2021) Chenglong Liu et al. BRITISH JOURNAL OF PHARMACOLOGY
- Emerging immune checkpoints in the tumor microenvironment: Implications for cancer immunotherapy
- (2021) Gaigai Wei et al. CANCER LETTERS
- Systematic review of combinations of targeted or immunotherapy in advanced solid tumors
- (2021) Aaron C Tan et al. Journal for ImmunoTherapy of Cancer
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update
- (2021) Bryan J. Schneider et al. JOURNAL OF CLINICAL ONCOLOGY
- Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
- (2020) Enli Liu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Discovery of the first potent proteolysis targeting chimera (PROTAC) degrader of indoleamine 2, 3-dioxygenase 1
- (2020) Mingxing Hu et al. Acta Pharmaceutica Sinica B
- Modulating the tumor immune microenvironment with sunitinib malate supports the rationale for combined treatment with immunotherapy
- (2020) Wei Li et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia
- (2020) Hanren Dai et al. Journal of Hematology & Oncology
- Clinical Challenges of Immune Checkpoint Inhibitors
- (2020) Maria de Miguel et al. CANCER CELL
- Oncolytic viruses for cancer immunotherapy
- (2020) Otto Hemminki et al. Journal of Hematology & Oncology
- Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance
- (2020) Emanuel Raschi et al. Targeted Oncology
- Clinical landscape of oncolytic virus research in 2020
- (2020) Nicholas Macedo et al. Journal for ImmunoTherapy of Cancer
- High-efficient generation of natural killer cells from peripheral blood with preferable cell vitality and enhanced cytotoxicity by combination of IL-2, IL-15 and IL-18
- (2020) Min Liu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- PROTACs: New method to degrade transcription regulating proteins
- (2020) Beichen Hu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- STING, a promising target for small molecular immune modulator: A review
- (2020) Yijun Liu et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Clinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment
- (2020) Norihiro Watanabe et al. MOLECULAR THERAPY
- Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia
- (2019) Juanjuan Zhao et al. Journal of Hematology & Oncology
- The anti-resection activity of the X protein encoded by Hepatitis Virus B
- (2019) Laifeng Ren et al. HEPATOLOGY
- Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors
- (2019) Fangjun Chen et al. JOURNAL OF CLINICAL INVESTIGATION
- A rationally designed peptide antagonist of the PD-1 signaling pathway as an immunomodulatory agent for cancer therapy
- (2019) Pottayil G Sasikumar et al. MOLECULAR CANCER THERAPEUTICS
- Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
- (2019) Filipe Martins et al. Nature Reviews Clinical Oncology
- Efficacy and safety of imiquimod 5% cream for basal cell carcinoma: a meta-analysis of randomized controlled trial
- (2019) Hong-Xia Jia et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression
- (2019) Qingsong Hu et al. NATURE IMMUNOLOGY
- Bispecific antibodies: a mechanistic review of the pipeline
- (2019) Aran F. Labrijn et al. NATURE REVIEWS DRUG DISCOVERY
- CAIX-specific CAR-T Cells and Sunitinib Show Synergistic Effects Against Metastatic Renal Cancer Models
- (2019) Huizhong Li et al. JOURNAL OF IMMUNOTHERAPY
- CAR-NK for tumor immunotherapy: Clinical transformation and future prospects
- (2019) Wenxiu Wang et al. CANCER LETTERS
- Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma
- (2019) Qiang Gao et al. CELL
- Immune checkpoint inhibitors: a promising anticancer therapy
- (2019) Sima Singh et al. DRUG DISCOVERY TODAY
- Progress in PD-1/PD-L1 pathway inhibitors: From biomacromolecules to small molecules
- (2019) Xin Lin et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Current challenges and emerging opportunities of CAR-T cell therapies
- (2019) Teresa R. Abreu et al. JOURNAL OF CONTROLLED RELEASE
- Design and application of oncolytic viruses for cancer immunotherapy
- (2019) Erkko Ylösmäki et al. CURRENT OPINION IN BIOTECHNOLOGY
- Blocking Tim-3 or/and PD-1 reverses dysfunction of tumor-infiltrating lymphocytes in HBV-related hepatocellular carcinoma
- (2018) Furong Liu et al. BULLETIN DU CANCER
- Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy
- (2018) Tina Cascone et al. Cell Metabolism
- The global landscape of cancer cell therapy
- (2018) Jun Tang et al. NATURE REVIEWS DRUG DISCOVERY
- Bispecific antibodies for cancer therapy: A review
- (2018) Anuradha Krishnamurthy et al. PHARMACOLOGY & THERAPEUTICS
- CAR T cell immunotherapy for human cancer
- (2018) Carl H. June et al. SCIENCE
- Targeting the IDO1/TDO2–KYN–AhR Pathway for Cancer Immunotherapy – Challenges and Opportunities
- (2018) Jae Eun Cheong et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap
- (2018) Wantong Song et al. Nature Communications
- Explaining Resistance to CAR T Cells
- (2018) Cancer Discovery
- Companies Scaling Back IDO1 Inhibitor Trials
- (2018) Cancer Discovery
- Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials
- (2018) Alberto Carretero-González et al. Oncotarget
- Mechanisms of Resistance to Immune Checkpoint Blockade
- (2018) David Liu et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Low-dose radiation conditioning enables CAR T cells to mitigate antigen escape
- (2018) Carl DeSelm et al. MOLECULAR THERAPY
- Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment
- (2018) Amanda Rosewell Shaw et al. Frontiers in Immunology
- Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors
- (2018) Daniel Y. Wang et al. JAMA Oncology
- A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
- (2018) Miguel F. Sanmamed et al. CELL
- Targeting IFNα to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance
- (2018) Yong Liang et al. Nature Communications
- Oncolytic virus immunotherapy: future prospects for oncology
- (2018) Junaid Raja et al. Journal for ImmunoTherapy of Cancer
- Natural Killer Cell-Based Immunotherapy for Cancer: Advances and Prospects
- (2018) Yuan Hu et al. Engineering
- PD-L1 induced by IFN-γ from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer
- (2017) Xiaohui Zhang et al. International Journal of Clinical Oncology
- FDA Approval of Tisagenlecleucel
- (2017) Peter B. Bach et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
- (2017) Jacob Schachter et al. LANCET
- De-novo and acquired resistance to immune checkpoint targeting
- (2017) Nicholas L Syn et al. LANCET ONCOLOGY
- Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
- (2017) Ugur Sahin et al. NATURE
- An immunogenic personal neoantigen vaccine for patients with melanoma
- (2017) Patrick A. Ott et al. NATURE
- Tumour-associated macrophages as treatment targets in oncology
- (2017) Alberto Mantovani et al. Nature Reviews Clinical Oncology
- Global metabolic reprogramming of colorectal cancer occurs at adenoma stage and is induced by MYC
- (2017) Kiyotoshi Satoh et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology
- (2017) Eddy W. Yue et al. ACS Medicinal Chemistry Letters
- Resistance to checkpoint blockade therapy through inactivation of antigen presentation
- (2017) Moshe Sade-Feldman et al. Nature Communications
- FDA Approves Second CAR T-cell Therapy
- (2017) Cancer Discovery
- A TLR3-Specific Adjuvant Relieves Innate Resistance to PD-L1 Blockade without Cytokine Toxicity in Tumor Vaccine Immunotherapy
- (2017) Yohei Takeda et al. Cell Reports
- T-cell receptor-engineered T cells for cancer treatment: current status and future directions
- (2017) Yu Ping et al. Protein & Cell
- Combined Anti-VEGF and Anti–CTLA-4 Therapy Elicits Humoral Immunity to Galectin-1 Which Is Associated with Favorable Clinical Outcomes
- (2017) Xinqi Wu et al. Cancer Immunology Research
- Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity
- (2017) Casey R. Ager et al. Cancer Immunology Research
- Corrigendum: Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
- (2017) Vivek Kumar Frontiers in Pharmacology
- CTLA-4 and PD-1 Pathways
- (2016) Elizabeth I. Buchbinder et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Reduced Expression of Histone Methyltransferases KMT2C and KMT2D Correlates with Improved Outcome in Pancreatic Ductal Adenocarcinoma
- (2016) J. B. N. Dawkins et al. CANCER RESEARCH
- Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
- (2016) Jianjun Gao et al. CELL
- Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
- (2016) Ana C. Anderson et al. IMMUNITY
- Cancer-induced heterogeneous immunosuppressive tumor microenvironments and their personalized modulation
- (2016) Tomonori Yaguchi et al. INTERNATIONAL IMMUNOLOGY
- Driving an improved CAR for cancer immunotherapy
- (2016) Xiaopei Huang et al. JOURNAL OF CLINICAL INVESTIGATION
- Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape
- (2016) Meenakshi Hegde et al. JOURNAL OF CLINICAL INVESTIGATION
- Melanoma and immunotherapy bridge 2015
- (2016) Vashisht G. Y. Nanda et al. Journal of Translational Medicine
- Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
- (2016) Corey J Langer et al. LANCET ONCOLOGY
- GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade
- (2016) Tessa Gargett et al. MOLECULAR THERAPY
- Genome-wide CRISPR screens reveal a Wnt–FZD5 signaling circuit as a druggable vulnerability of RNF43-mutant pancreatic tumors
- (2016) Zachary Steinhart et al. NATURE MEDICINE
- Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination
- (2016) Celine Boutros et al. Nature Reviews Clinical Oncology
- T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
- (2016) Eric Tran et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia
- (2016) Rizwan Romee et al. Science Translational Medicine
- Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
- (2016) Shohei Koyama et al. Nature Communications
- Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model
- (2016) Eloah Rabello Suarez et al. Oncotarget
- Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors
- (2016) MacLean Hall et al. Journal for ImmunoTherapy of Cancer
- Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs
- (2015) Soranobu Ninomiya et al. BLOOD
- Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
- (2015) Chih-Hao Chang et al. CELL
- Fc receptor inside-out signaling and possible impact on antibody therapy
- (2015) Arianne M. Brandsma et al. IMMUNOLOGICAL REVIEWS
- Cancer immunotherapy: harnessing the immune system to battle cancer
- (2015) Yiping Yang JOURNAL OF CLINICAL INVESTIGATION
- Case Report of a Fatal Serious Adverse Event Upon Administration of T Cells Transduced With a MART-1-specific T-cell Receptor
- (2015) Joost H van den Berg et al. MOLECULAR THERAPY
- Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
- (2015) Christina Twyman-Saint Victor et al. NATURE
- Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
- (2015) Stefani Spranger et al. NATURE
- Oncolytic viruses: a new class of immunotherapy drugs
- (2015) Howard L. Kaufman et al. NATURE REVIEWS DRUG DISCOVERY
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoantigens in cancer immunotherapy
- (2015) T. N. Schumacher et al. SCIENCE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade
- (2015) Juan Fu et al. Science Translational Medicine
- Overcoming T cell exhaustion in infection and cancer
- (2015) Kristen E. Pauken et al. TRENDS IN IMMUNOLOGY
- Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
- (2015) W. Peng et al. Cancer Discovery
- LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model
- (2015) Ruea-Yea Huang et al. Oncotarget
- Doxil Synergizes with Cancer Immunotherapies to Enhance Antitumor Responses in Syngeneic Mouse Models
- (2015) Jonathan Rios-Doria et al. NEOPLASIA
- The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function
- (2014) Robert J. Johnston et al. CANCER CELL
- Pilot study of a novel combination of two therapeutic vaccines in advanced non-small-cell lung cancer patients
- (2014) Zaima Mazorra Herrera et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptor-Transduced Human T cells in Solid Tumors
- (2014) E. K. Moon et al. CLINICAL CANCER RESEARCH
- Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
- (2014) Liufu Deng et al. JOURNAL OF CLINICAL INVESTIGATION
- Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy
- (2014) S. L. Highfill et al. Science Translational Medicine
- Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade
- (2014) Z. A. Cooper et al. Cancer Immunology Research
- Invariant natural killer T cells regulate anti-tumor immunity by controlling the population of dendritic cells in tumor and draining lymph nodes
- (2014) Karsten A Pilones et al. Journal for ImmunoTherapy of Cancer
- Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells
- (2013) L. B. John et al. CLINICAL CANCER RESEARCH
- Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma
- (2013) Nienke van Rooij et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer Regression and Neurological Toxicity Cases After Anti-MAGE-A3 TCR Gene Therapy
- (2013) Vincent G. Brichard et al. JOURNAL OF IMMUNOTHERAPY
- Cancer Immunotherapy
- (2013) J. Couzin-Frankel SCIENCE
- Abstract 2850: Demonstration of anti-tumor efficacy in multiple preclinical cancer models using a novel peptide inhibitor (Aurigene-012) of the PD1 signaling pathway
- (2012) Pottayil G. Sasikumar et al. CANCER RESEARCH
- BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice
- (2012) C. Liu et al. CLINICAL CANCER RESEARCH
- Sustained effector function of IL-12/15/18–preactivated NK cells against established tumors
- (2012) Jing Ni et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Efficacy of Adoptive Cell Transfer of Tumor-infiltrating Lymphocytes After Lymphopenia Induction for Metastatic Melanoma
- (2012) Shari Pilon-Thomas et al. JOURNAL OF IMMUNOTHERAPY
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-TIM3 Antibody Promotes T Cell IFN- -Mediated Antitumor Immunity and Suppresses Established Tumors
- (2011) S. F. Ngiow et al. CANCER RESEARCH
- Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
- (2011) S. A. Rosenberg et al. CLINICAL CANCER RESEARCH
- Tumor Infiltrating Lymphocyte Therapy for Metastatic Melanoma: Analysis of Tumors Resected for TIL
- (2010) Stephanie L. Goff et al. JOURNAL OF IMMUNOTHERAPY
- Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies
- (2010) Frank R. Brennan et al. mAbs
- Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model
- (2009) Claire Banissi et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Optimization of Fc-mediated effector functions of monoclonal antibodies
- (2009) William R Strohl CURRENT OPINION IN BIOTECHNOLOGY
- Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1
- (2009) Dong-Ming Kuang et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Anti-CTLA4 Antibody–Induced Lupus Nephritis
- (2009) Fouad Fadel et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now